United States Patent 8,916,131: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 8,916,131, titled "Radiopharmaceutical composition," is a significant patent in the field of medical diagnostics, particularly in the area of radiopharmaceuticals. This patent, issued to inventors who have developed a novel radiopharmaceutical composition, addresses critical issues in the diagnosis of diseases involving abnormal amyloid deposition.
Patent Overview
Invention Description
The patent describes a radiopharmaceutical composition that includes a compound of a specific formula, designed for use in diagnostic imaging techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT)[4].
Key Components
- The radiopharmaceutical composition comprises an amyloid-binding compound, which is crucial for diagnosing disease states involving abnormal amyloid deposition.
- The composition includes polysorbate as an excipient, which helps in reducing the loss of the thioflavin derivative compounds to dispensing kit components.
- The patent also details the inclusion of optional components such as buffers, lyophilisation aids, stabilization aids, solubilisation aids, and bacteriostats to improve the stability and shelf-life of the pharmaceutical[4].
Scope of the Patent
Claims
The patent includes several claims that define the scope of the invention:
- Claim 1: A radiopharmaceutical composition comprising a compound of Formula Ia, which includes radioactive carbon or a radioactive halogen.
- Claim 2: The composition includes polysorbate as an excipient to prevent retention on dispensing kit components.
- Claim 3: Methods for preparing the radiopharmaceutical composition.
- Claim 4: Uses of the radiopharmaceutical composition in diagnostic imaging[4].
Dependent Claims
The patent also includes dependent claims that further specify the composition and its components, such as the type of radioactive halogen used (e.g., 123I or 18F) and the specific structure of the compound (e.g., Formula Ia with Y_a being —NR_1R_2)[4].
Patent Landscape
Prior Art
The patent acknowledges prior art compositions that encountered problems such as strong retention on dispensing kit components. The current invention overcomes these issues by incorporating polysorbate as an excipient[4].
International Classification
The patent is classified under various international classifications, including A61K47/06, A61K47/08, and A61K47/10, which pertain to organic compounds used in medical preparations. It also falls under A61P25/00 and A61P25/28, which relate to drugs for disorders of the nervous system, including neurodegenerative disorders[4].
Global Patent Family
To understand the global reach of this patent, one would need to search international patent databases such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO)[1].
Search and Analysis Tools
USPTO Resources
For a comprehensive analysis, one can use the USPTO's Patent Public Search tool, which provides enhanced access to prior art and allows users to search for related applications and citations. The Global Dossier service is also useful for viewing the patent family and file histories of related applications from participating IP Offices[1].
Patent Claims Research Dataset
The USPTO's Patent Claims Research Dataset can be utilized to analyze the claims and scope of the patent in detail. This dataset provides detailed information on claims from US patents and applications, including claim-level statistics and document-level statistics[3].
Economic and Practical Implications
Market Impact
The invention has significant implications for the diagnosis and treatment of neurodegenerative diseases. By providing a stable and effective radiopharmaceutical composition, it can improve diagnostic accuracy and patient outcomes.
Competitive Landscape
The patent landscape in the field of radiopharmaceuticals is highly competitive. Other patents, such as those related to the use of cyclodextrins as radiation stabilizers, also play a crucial role in this field[5].
Legal Status and Expiration
Current Status
As of the current date, the patent is active, but its legal status and expiration dates should be verified through the USPTO or other reliable sources[2][4].
Key Takeaways
- Radiopharmaceutical Composition: The patent describes a novel radiopharmaceutical composition for diagnostic imaging, particularly for diseases involving abnormal amyloid deposition.
- Polysorbate as Excipient: The inclusion of polysorbate addresses issues of retention on dispensing kit components.
- Claims and Scope: The patent includes multiple claims defining the composition, preparation methods, and uses.
- Patent Landscape: The invention is part of a broader landscape of radiopharmaceutical patents, with classifications under A61K and A61P.
- Search and Analysis Tools: Utilize USPTO resources and the Patent Claims Research Dataset for detailed analysis.
FAQs
Q: What is the primary use of the radiopharmaceutical composition described in US Patent 8,916,131?
A: The primary use is for diagnostic imaging in diseases involving abnormal amyloid deposition, using techniques such as PET and SPECT.
Q: What is the role of polysorbate in the radiopharmaceutical composition?
A: Polysorbate is used as an excipient to prevent the retention of the thioflavin derivative compounds on dispensing kit components.
Q: How can one search for related patents and prior art?
A: Use the USPTO's Patent Public Search tool and the Global Dossier service to search for related applications and citations.
Q: What are the international classifications for this patent?
A: The patent is classified under A61K47/06, A61K47/08, A61K47/10, A61P25/00, and A61P25/28.
Q: Where can one find detailed information on the claims and scope of US patents?
A: The USPTO's Patent Claims Research Dataset provides detailed information on claims from US patents and applications.
Sources
- USPTO: Search for patents - USPTO.
- PharmaCompass: US Patent 8916131 | Expiration | Dates - PharmaCompass.com.
- USPTO: Patent Claims Research Dataset - USPTO.
- Google Patents: US8916131B2 - Radiopharmaceutical composition - Google Patents.
- PubChem: Use of cyclodextrins as radiation stabilizers - Patent JP-2022553266 ...
